WO1996008527A1 - Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere - Google Patents
Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere Download PDFInfo
- Publication number
- WO1996008527A1 WO1996008527A1 PCT/RU1995/000201 RU9500201W WO9608527A1 WO 1996008527 A1 WO1996008527 A1 WO 1996008527A1 RU 9500201 W RU9500201 W RU 9500201W WO 9608527 A1 WO9608527 A1 WO 9608527A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stacking
- oligomer
- cell
- ορτο
- spiralized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/775—Phenolic resins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- John 2.6-Di (trans.butyl-4 ⁇ letilf_nol) is affected by oxidants, these are synthesis inhibitors ⁇ and free radical processes. 5
- the product is circulated.
- Biological method is not installed.
- the unit is not installed.
- the device is operated by breathing methods.
- the first transformer reacting with the family of variable systems: ⁇ D' ⁇ ⁇ -oxidase, succinate-system and system, (January 19, 1979) “The Possession of Assassins and Their Analogs on the Asset - 5 Parts of the Entertainment Chain”, p. 969–974).
- ⁇ dna ⁇ narrow ⁇ aya ⁇ blas ⁇ is ⁇ lz ⁇ vaniya
- sl ⁇ zhnaya ⁇ e ⁇ n ⁇ l ⁇ giya ⁇ lucheniya (mn ⁇ g ⁇ s ⁇ adiyny ⁇ i ⁇ liches ⁇ y sin ⁇ ez or e ⁇ s ⁇ a ⁇ shya of ⁇ li ⁇ - ⁇ ganizm ⁇ v with ⁇ sleduschim ⁇ ntsen ⁇ i ⁇ vaniem and ⁇ chis ⁇ y) ⁇ n ⁇ si ⁇ eln ⁇ nevys ⁇ aya e ⁇ e ⁇ ivn ⁇ s ⁇ za ⁇ udnyayu ⁇ is ⁇ lz ⁇ -
- the claimed stacking - a synchronized orthopedic and regulating function of bioenergetic systems, erectile dysfunction and erythematosus are at the root of the disease.
- the task of creating a new material is provided - a stacking-synchronized, non-resident, non-resident
- 25 zhaschy ge ⁇ sayi ⁇ l ⁇ lineynye yad ⁇ a, ⁇ liches ⁇ v ⁇ ⁇ y ⁇ on vi ⁇ s ⁇ i ⁇ ali v ⁇ ichn ⁇ y s ⁇ u ⁇ u ⁇ y sheepvann ⁇ g ⁇ ⁇ lig ⁇ me ⁇ a ⁇ avn ⁇ ⁇ 2.6 d ⁇ 3.0 ⁇ i e ⁇ m in s ⁇ i ⁇ ali v ⁇ ichn ⁇ y s ⁇ zg ⁇ u ⁇ y ⁇ lig ⁇ me ⁇ a s ⁇ de ⁇ zhi ⁇ sya b ⁇ lee I, n ⁇ not b ⁇ lee 10 vi ⁇ v.
- the embodiment of the claimed invention is more frequent, that the staking-personalized version of 10 causes a significant increase in the rate of 2-day-2 6- ⁇ and oxyphenylene).
- the claimed stacking-socialized cyclic connection is a long circuit with a length of 3 to 30 small links.
- the inventive stacking-encrypted oligomera contains cyclichexaline linear cores connected between themselves in the through-through connection _> -connection.
- the 35 available oligomers are sourced from polyphenylene or gasoline poisons, which are quantitatively poisonous . - 5 -
- the wrestling club has discontinued the second-hand construction of the club, which is equal to 2.6 to 3.0.
- the invention is due to the fact that they can play the polluters, which are located at the expense of the central part of it. 3
- these groups such as hydroxyls, alkoxy-ethers, sulfates, hydroxyalkylamines
- octadela is shla'lin, gzksaceidlamine, ⁇ . butylamine.
- the method of using atomic and atomic methods is based on the use of atomic potentials. ” Pa ⁇ agle ⁇ y s ⁇ i ⁇ ali, ⁇ uyu ⁇ b ⁇ azue ⁇ m ⁇ le ⁇ ula ⁇ the investigated em ⁇ g ⁇ s ⁇ edine ⁇ iya her step chisl ⁇ m ⁇ n ⁇ me ⁇ v on ⁇ din vi ⁇ and ee ⁇ adius, calculated ⁇ ⁇ dina ⁇ am s ⁇ ve ⁇ s ⁇ vuschi ⁇ ⁇ che ⁇
- Table I provides the results of the results obtained, herewith, ⁇ - the difference in the energy of the battery and the sum of the energy of the components.
- the transverse isomerase does not necessarily occur.
- Aggregates are cached in a series of stacking
- connection of the calculation method is the real ⁇ monome- Radius corner, 8 degrees apart. X on fire
- ⁇ ⁇ ablitse 3 ⁇ veden ⁇ s ⁇ s ⁇ avl ⁇ nie s ⁇ e ⁇ alny ⁇ ⁇ a ⁇ a ⁇ e- ⁇ is ⁇ i ⁇ s ⁇ e ⁇ ssh ⁇ g-s ⁇ i ⁇ aliz ⁇ zashsh ⁇ ⁇ lig ⁇ me ⁇ v ⁇ - ⁇ enilena 0 gid ⁇ sili ⁇ vanny ⁇ 2, 3,5- ⁇ l ⁇ : _en_ya and ⁇ i ⁇ sib ⁇ nz ⁇ la.
- P ⁇ i is ⁇ lz ⁇ vanii s ⁇ e ⁇ ing-s ⁇ i ⁇ shshz ⁇ vanny ⁇ ⁇ - ⁇ li- g ⁇ me ⁇ v of ⁇ aches ⁇ ve ⁇ egulya ⁇ a bi ⁇ en ⁇ rge ⁇ iches ⁇ i ⁇ sis ⁇ em in s ⁇ av ⁇ egulya ⁇ a na ⁇ yadu with a ⁇ ivnygl nachal ⁇ gl vzedya ⁇ vesche- s ⁇ va, ⁇ blatsaschie slugebnymi ⁇ un ⁇ tsiyami: ⁇ azbavi ⁇ eli (di ⁇ - ⁇ illi ⁇ vannaya veda, ⁇ izi ⁇ l ⁇ giches ⁇ y ⁇ as ⁇ v ⁇ and ⁇ .d.) s ⁇ u ⁇ u ⁇ b ⁇ az ⁇ va ⁇ eli ( ⁇ a ⁇ mal ), souls and ⁇ . ⁇ .
- Zayavlyaeglye bi ⁇ l ⁇ giches ⁇ i-a ⁇ ivnye vesches ⁇ va m ⁇ gu ⁇ by ⁇ is ⁇ lz ⁇ vany in mi ⁇ bi ⁇ l ⁇ giches ⁇ y ⁇ myshlenn ⁇ s ⁇ i ⁇ a ⁇ ⁇ egulya ⁇ ⁇ s ⁇ a ⁇ le ⁇ or i ⁇ ⁇ un ⁇ tsi ⁇ ni ⁇ uschey a ⁇ ivn ⁇ s ⁇ i in ⁇ sme ⁇ i ⁇ e - in ⁇ aches ⁇ ze a ⁇ ivn ⁇ g ⁇ beginning in glazya ⁇ , ⁇ ema ⁇ , -sham ⁇ unya ⁇ ⁇ -l ⁇ s ⁇ na ⁇ , zubny ⁇ ⁇ as ⁇ a ⁇ , -in sels ⁇ m . ⁇ eyay ⁇ ve. - in the quality of supplements or products, ⁇ ⁇ - in the quality of supplements or products, ⁇ ⁇ -
- hypoxic different genesis infectious diseases, epilepsy.
- LB 50 when administered internally, livestock: Krumbs, children and mumps are 1350 g. / G / kg and 760-920 mg / kg - both when administered internally.
- the inventive regulator has been studied in the experiment on microorganisms, isolated live cells of animals and people, and people, in human life, in humans.
- an overdose device With a dose of 100 mg / l, cell mobility increases by 5 7.3 mV compared to the control population.
- the introduction of an overdose device is a physical movement of live cells, which is associated with a change in their bioenergetic functions.
- the claimed compound is 5.3 ⁇ 0.4 23 ⁇ 1.8 3.75 ⁇ 0. ⁇ 7 stacking-and-ligated oligon-2- (3,6-dioxi-phenylene) -sulphate
- Table 5 The declaration of the manufacture of fumes for smoke and disinfecting isothermal media depends on the quantity of the substance - (num. 14).
- the price was estimated at the state of the circuits of the electric power supply of the central part of the territory of the Republic of Korea and the United Kingdom.
- the gypsy state was reached by the border of the country. Yes.
- the stages of the transfusion of the business group entered the group enriched with acid.
- ⁇ ⁇ ablitse 8 ⁇ eds ⁇ avleny data ⁇ s ⁇ n ⁇ sheniyu ⁇ n- tsen ⁇ atsii ⁇ islenn ⁇ y ⁇ my ⁇ av ⁇ enin ⁇ v ⁇ v ⁇ ss ⁇ an ⁇ vi- ⁇ eln ⁇ y ⁇ me ( ⁇ ⁇ ⁇ tsialn ⁇ mu pressure ⁇ isl ⁇ da ( ⁇ ⁇ ), ⁇ isli ⁇ eln ⁇ -v ⁇ ss ⁇ an ⁇ vi ⁇ eln ⁇ mu ⁇ entsialu ⁇ vi ( ⁇ ⁇ i administered 7% v ⁇ dn ⁇ g ⁇ ⁇ as ⁇ v ⁇ a occidentalvann ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a in d ⁇ - se 35 mg / kg, as well as the reduction of glucose (C hl ) and the content of small acid (C._) with the introduction of 10 mg / kg of 7 $ aqueous solution.
- Table 3 The effect of activating the activity in the brain by filling in the box (through the ring is given)
- Table 9 The stimulating effect of the claimed drug on the cultivation of the culture of the Sha-G7 community and the cultivation of the library on a download.
- the antihypoxic activity of the claimed drug has been studied for various types of hypoxia in the rat and the ⁇ circle.
- ⁇ Antiperspirants used unpredictable masses of 1.5–3.5 kg and food accents from 200–220 g.
- Hypoxia was called-.-. Gypsy - an exposition of animals in a bar-ka-valeru at critical heights of 11-12 cm; 2. hemostatic shock - ⁇ ⁇ ⁇ think;;;;; 3. The circulatory - primitive sleepy A. r.therapy.
- Non-oral drugs were introduced internally by the administration of Nembutal (40.0 mg / kg).
- the development of hypothesis was encouraged by a dynamic dynamic process.
- the claimed and ⁇ e ⁇ a ⁇ a ⁇ ⁇ e ⁇ a ⁇ a ⁇ y s ⁇ avneniya (ubi ⁇ in ⁇ n and tsi ⁇ m C) vv ⁇ dili zhiv ⁇ - nym ⁇ dn ⁇ a.z ⁇ v ⁇ vnu ⁇ ib ⁇ yushinn ⁇ sleduyuschigl ⁇ b ⁇ az ⁇ m: a) claimed ⁇ e ⁇ a ⁇ a ⁇ - s ⁇ e ⁇ ing-sshg ⁇ aliz ⁇ vanny ⁇ lig ⁇ -1,2- (3,6-di ⁇ si ⁇ enilen) - ⁇ i ⁇ sul ⁇ a ⁇ na ⁇ iya ( ⁇ 5 ) in an optimal dose of 30 mg / kg in the form of a 1% solution; b) killed in the form of a solution from a calculation of
- Dili was the great runaway of the waters. After this, the Eglbrons were incubated at a temperature of 37 ° for 2 hours, a virus was introduced without the aid of the Castle ( ⁇ ⁇ ⁇ ) at a dose of 10 VD / ⁇ . ⁇ y. The infected embryos were additionally incubated at the age of 5–48 hours and determined the presence of viral agglutination in them. The results are presented in Table II.
- the drugstore. ⁇ the quantity of business is the average.
- DOSE (mg / kg) of embryo viruses / homeopathy, in the living area of the viral protection of the viral part of the stem
- 8.0 ml of venous rounds were delivered to the hospital, which consisted of I ml of medium 199 tablets ⁇ ___ a, and a nominal number ⁇ 5017, and a flow rate of 5 min. , separated the drug layer and suspended it in 1-2 ulls of medium 199.
- the declared impaired appliance is efficient and the best after cleaning. Actually, a staggered-extended olig- 2, 2- (3,4,6-triplexiphenylene) showed a high effeciency in the protection of the resource.
- the on-site group of sick people made up. ⁇ 20 to 43 people.
- the claimed regulator With the use of the claimed regulator, there was a great deal of difficulty with heavy machinery; Already in the next few hours, the indicators of central hemodynamics are improving and stabilizing, the heart rate is increasing. There is a peri- odic circulation. The consumption of acid is increased, the content of lactate and water is reduced at a lower rate, and the degree of adidosis is reduced. and hyperation.
- the resultant compound is Olig_- ⁇ , 2- (3,4,6- ⁇ ##
- ⁇ __ ⁇ 0) has a molecular mass of 1300, a melting point> 350 ° ⁇ .
- the structure of the obtained compounds is analyzed by methods of the resonant resonance, the infrared and the ultraparalytic spectroscopy.
- 1,2- (3,4,6- ⁇ -oxo-phenylated) is electrically protected by various values of ⁇ in the presence of 7 ⁇ urea.
- Oligon-1,2- (3,4,6- ⁇ and oxi-phenyl), obtained with the aid of the United States, is listed in T.A. person 16.
- the intact olite- ⁇ , 2- (3, 4, 6-triplexiphenyl) complex is brushed by the following characteristic areas:
- the spacing step is 3.4 ⁇ 0.2 ⁇
- the best result is that our connection is 850 g.
- the resulting oligome, 2- (3,4,6-thermo-phenylated) has a very high temperature of 800, a melting point> 350 ° ⁇ . 15
- the structure of the resulting compounds is analyzed by methods of the magnetic resonance., Infectious and ultra-sensitive spectroscopy. For the sake of comparability of the data obtained, they use tsiboxybenzene in the form of a large compound.
- the degree of politlerization of the resulting compound is equal to 6. 20 Parameters of the strict spiral, 2- (3,4,6-transitive) are analogous to the equivalent.
- the best compound obtained was 750.6.
- the resulting oligomer has a molecular mass of 400, a melting point> 350 ° C. 30
- the structure of the obtained compounds is analyzed in a similar way to I. For the compilation of the obtained data, the transmission is supported by transverse sibenzene.
- the infectious incidence of the resulting occlusion plays the following char- acteristic areas: 825, 1085, II 90, 1415, 1496, 1496. 5 ULTRA SPECTRUM OF THE INCREASED ORGANIZATION
- the yield of the target product is 2.645% (66 $ of theoretical value of 30 calculation results).
- the flask is blown out and slowed down by heating and the mixture is slowed down, after which the temperature of the mixture is brought to 20 ° C.
- the process of ligomerization is processed for 5 clay, then the alloy is cooled, the product is removed, it is electrically gummed and electromagnetized.
- the product dries before a vacant long-standing mass. The release is 5.0 g ($ 40.3 from the theoretical). 25
- the product has been processed by the U-, UF- and I-processes. The content of A. zot. - $ 2.54 (theoretical - $ 2.59).
- a large oligogen aminopenil which is a 30-year self-storing-improved olymphenomenon, remains the same for the following, 8th case.
- ⁇ ⁇ e ⁇ g ⁇ lugo ⁇ lbu equipped ⁇ b ⁇ a ⁇ nym ⁇ l ⁇ dilni- ⁇ gl, and gleshal ⁇ y ⁇ duvaegluto ine ⁇ nym gaz ⁇ m, ⁇ meschayu ⁇ ⁇ a- s ⁇ v ⁇ 35 0.4 g (5 * 10 m ⁇ l) ⁇ a ⁇ a.-benz ⁇ in ⁇ na in 40 ml of acetone ⁇ na.
- the appliance is heated to 40 ° C and is mixed, and it is heated at the same temperature of 1.345 g. - 31 -
- the mixture is heated to the temperature of the boiling point of the solvent and the reaction during the first hour. After leaving the factory, the product has been washed and dry and vacuumed before losing weight ..
- Allergy-related polio which is a self-contained staking-modified code, is gradually reduced, which is equal to 5.
- the product is processed by the methods of IS, UF, and G.S.-sectional techniques.
- the degree of compliance is 5, the average weight is 600.
- the nitrogen content is 2.32 $ (theoretical - 2.29 $).
- the claimed invention finds use in the past, agricultural, in the case of medicinal products, is used, and may also be used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'ortho-oligomère à empilage spiralé de l'invention contient des anneaux hexa-cyclolinéaires en nombres équivalents à 2,6 - 3,0 par tour de l'hélice de la structure secondaire de l'oligomère, ladite hélice contenant plus d'un tour mais pas plus de dix tours. L'invention concerne également un régulateur de systèmes bioénergétiques cellulaires dans des eukaryotes et prokaryotes contenant l'ortho-oligomère à empilage spiralé de l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU94033297 | 1994-09-14 | ||
RU94033297 | 1994-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996008527A1 true WO1996008527A1 (fr) | 1996-03-21 |
Family
ID=20160416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1995/000201 WO1996008527A1 (fr) | 1994-09-14 | 1995-09-12 | Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1996008527A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018758A1 (fr) * | 1996-10-30 | 1998-05-07 | Zakrytoe Aktsionernoe Obschestvo 'korporatsia Oliphen' | Sel de sodium de l'acide [poly-(2,5-dihydroxyphenylene)]-4-thiosulfurique de structure lineaire, en tant que regulateur du metabolisme cellulaire, et procede de production associe |
RU2120297C1 (ru) * | 1997-10-31 | 1998-10-20 | Товарищество с ограниченной ответственностью "Дека-Н" | Способ нормализации обменных процессов в клетке и препарат для этих целей |
RU2175317C1 (ru) * | 2000-12-01 | 2001-10-27 | Соболев Дмитрий Владимирович | Натриевая соль поли(пара-дигидрокси-пара-фенилен)тиосульфокислоты, обладающая супероксидазной активностью, и способ ее получения |
WO2010074591A1 (fr) | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Amides de créatine, procédé de production, et produit possédant une action neuroprotectrice |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU598911A1 (ru) * | 1976-09-23 | 1978-03-25 | Сумгаитский Филиал Ордена Трудового Красного Знамени Института Нефтехимических Процессов Им.Акад.Ю.Г.Мамедалиева Ан Азербайджанской Сср | Способ получени полигидрохинона |
SU1016316A1 (ru) * | 1982-01-26 | 1983-05-07 | Институт Хлорорганического Синтеза Ан Азсср | Способ получени полигидрохинона |
SU1052512A1 (ru) * | 1982-06-14 | 1983-11-07 | Всесоюзный Научно-Исследовательский Институт Особо Чистых Биопрепаратов | Алкиламинозамещенные производные поли-( @ -диокси- @ -фенилена) в качестве маслорастворимых антиоксидантов |
-
1995
- 1995-09-12 WO PCT/RU1995/000201 patent/WO1996008527A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU598911A1 (ru) * | 1976-09-23 | 1978-03-25 | Сумгаитский Филиал Ордена Трудового Красного Знамени Института Нефтехимических Процессов Им.Акад.Ю.Г.Мамедалиева Ан Азербайджанской Сср | Способ получени полигидрохинона |
SU1016316A1 (ru) * | 1982-01-26 | 1983-05-07 | Институт Хлорорганического Синтеза Ан Азсср | Способ получени полигидрохинона |
SU1052512A1 (ru) * | 1982-06-14 | 1983-11-07 | Всесоюзный Научно-Исследовательский Институт Особо Чистых Биопрепаратов | Алкиламинозамещенные производные поли-( @ -диокси- @ -фенилена) в качестве маслорастворимых антиоксидантов |
Non-Patent Citations (2)
Title |
---|
AKADEMIA NAUK, SSSR, (Puschino), "Reaktsii Zhivykh Sistem I Sostoyanie Energeticheskogo Obmena", 1979, pages 186-187. * |
IV Konferentsia, Tezisy Dokladov, 2-4 June 1992, Onubl. 1993, RAN, Institut Khimicheskoi Fiziki, (Moscow), Vol. 16, "Bioantioksidant", pages 126-128. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998018758A1 (fr) * | 1996-10-30 | 1998-05-07 | Zakrytoe Aktsionernoe Obschestvo 'korporatsia Oliphen' | Sel de sodium de l'acide [poly-(2,5-dihydroxyphenylene)]-4-thiosulfurique de structure lineaire, en tant que regulateur du metabolisme cellulaire, et procede de production associe |
EA001563B1 (ru) * | 1996-10-30 | 2001-04-23 | Закрытое Акционерное Общество " Корпорация Олифен" | Натриевая соль поли-(2,5-дигидрокси-фенилен)-4-тиосульфокислоты линейного строения как регулятор метаболизма клетки и способ ее получения |
RU2120297C1 (ru) * | 1997-10-31 | 1998-10-20 | Товарищество с ограниченной ответственностью "Дека-Н" | Способ нормализации обменных процессов в клетке и препарат для этих целей |
RU2175317C1 (ru) * | 2000-12-01 | 2001-10-27 | Соболев Дмитрий Владимирович | Натриевая соль поли(пара-дигидрокси-пара-фенилен)тиосульфокислоты, обладающая супероксидазной активностью, и способ ее получения |
WO2010074591A1 (fr) | 2008-12-24 | 2010-07-01 | Закрытое Акционерное Общество "Beptekc" | Amides de créatine, procédé de production, et produit possédant une action neuroprotectrice |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cazarolli et al. | Follow-up studies on glycosylated flavonoids and their complexes with vanadium: their anti-hyperglycemic potential role in diabetes | |
WO1983002892A1 (fr) | Preparation medicinale possedant un effet antinicotine et son procede d'obtention | |
WO1990008135A1 (fr) | Monohydrate d'hydrochlorure d'acide ethyle ester 6-brome-5-hydroxy-4-dimethyle-aminomethyle-1-methyle-2-phenylthiomethyle indole-3-carboxylique, son procede d'obtention et preparation pharmaceutique presentant une activite antivirale, de stimulation d'interferon et d'immunomodulation basee sur ledit compose | |
WO1995017902A1 (fr) | Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices | |
WO1989006134A1 (fr) | Preparation pharmaceutique pour traiter des etats immunodeficitaires | |
WO1999007699A1 (fr) | Modulateur immunologique ayant une activite antimicrobienne et anti-mycobacterienne, procede de production de ce modulateur et preparation pharmaceutique permettant de traiter les mycobacterioses ainsi que les affections chroniques et non specifiques des poumons, les maladies sexuellement transmissibles et le deficit immuni | |
EP0363491A4 (en) | Bacterial preparation for prophylaxis and treatment of inflammatory processes and allergic diseases | |
WO1996008527A1 (fr) | Ortho-oligomere a empilage spirale et regulateur de systemes bio-energetiques cellulaires dans des eukaryotes et des prokaryotes bases sur ledit oligomere | |
WO1997037651A1 (fr) | Procede de preparation d'un medicament (trecresan) ayant une action nootrope | |
WO2003072124A1 (fr) | Methode d'induction de differentiation cellulaire | |
RU2105000C1 (ru) | Натриевая соль [поли-(2,5-дигидрокси-фенилен)]-4-тиосульфокислоты как регулятор метаболизма клетки и способ ее получения | |
Mutch | Synthetic magnesium trisilicate: Its action in the alimentary tract | |
WO2002024610A2 (fr) | Procede de production d'un antineoplasique | |
RU2281957C1 (ru) | Водорастворимый натрий-, кальций-, железополигалактуронат, стимулирующий процесс кроветворения | |
WO1999018083A1 (fr) | N,n'-(sulfonyldi-1, 4-phenylene) bis (n'',n''- dimethylformamidin)-1, 2,3,4-tetrahydro- 6-methyl-2, 4-dioxo-5-pyrimidinsulfonate stimulant le metabolisme cellulaire et possedant une action immunotrope et antibacterienne, et procede de production | |
RU2648451C1 (ru) | Церебропротекторное средство | |
RU2235550C2 (ru) | Лекарственное средство бионормализующего действия и способ его получения | |
WO1997045530A1 (fr) | Utilisation de souches de streptococcus faecium et composition a base de ces souches | |
WO1999025718A1 (fr) | DERIVES DE 5H-PYRANO[2,3-d:6,5-d']DIPYRIMIDINE AYANT UNE ACTION ANTIBACTERIENNE, ANTIVIRALE ET IMMUNO-MODULATRICE | |
RU2707119C2 (ru) | Способ коррекции биохимического статуса новорожденных телят | |
WO1995008318A2 (fr) | Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse | |
WO2004064849A1 (fr) | Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale | |
WO2002043740A1 (fr) | Procede de fabrication d'un produit antiviral immunotropique | |
RU2818489C1 (ru) | Комплексное соединение 5-аминосалициловой кислоты с окисленным пектином, проявляющее противоязвенную активность, и способ его получения | |
WO1999016456A1 (fr) | Preparation ayant une activite biologique, complexe de preparations et procede de stimulation immunologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BG BR BY CA CN JP KP MN MX UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WD | Withdrawal of designations after international publication |
Free format text: MN,US,VN |
|
122 | Ep: pct application non-entry in european phase |